Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

Lotfi Benboubker; Meletios Athanasios Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R Belch; Michele M Cavo; Antonello I Pinto; Katja Christina Weisel; Heinz Ludwig; Nizar Jacques Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie D Cavenagh; Catarina Geraldes; Jejung Lee; Christine Chen; Albert Oriol; Javier De La Rubia; Lugui Qiu; Darrell J White; Daniel Binder; Kenneth Carl Anderson; Jean Paul Fermand; Philippe Moreau; Michel Attal; Robert D Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette L Ervin-Haynes; Herve Avet-Loiseau; Cyrille Hulin; Thierry Facon

doi:10.1056/NEJMoa1402551

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

Lotfi Benboubker
, Meletios Athanasios Dimopoulos
, Angela Dispenzieri
, John Catalano
, Andrew R Belch
, Michele M Cavo
, Antonello I Pinto
, Katja Christina Weisel
, Heinz Ludwig
, Nizar Jacques Bahlis
, Anne Banos
, Mourad Tiab
, Michel Delforge
, Jamie D Cavenagh
, Catarina Geraldes
, Jejung Lee
, Christine Chen
, Albert Oriol
, Javier De La Rubia
, Lugui Qiu

Darrell J White, Daniel Binder, Kenneth Carl Anderson, Jean Paul Fermand, Philippe Moreau, Michel Attal, Robert D Knight, Guang Chen, Jason Van Oostendorp, Christian Jacques, Annette L Ervin-Haynes, Herve Avet-Loiseau, Cyrille Hulin, Thierry Facon

Research output: Contribution to journal › Article › Research › peer-review

730 Citations (Scopus)

Abstract

Background: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. Methods: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. Results: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P

Original language	English
Pages (from-to)	906 - 917
Number of pages	12
Journal	The New England Journal of Medicine
Volume	371
Issue number	10
DOIs	https://doi.org/10.1056/NEJMoa1402551
Publication status	Published - 2014

Access to Document

10.1056/NEJMoa1402551

Cite this

Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M. M., Pinto, A. I., Weisel, K. C., Ludwig, H., Bahlis, N. J., Banos, A., Tiab, M., Delforge, M., Cavenagh, J. D., Geraldes, C., Lee, J., Chen, C., Oriol, A., De La Rubia, J., ... Facon, T. (2014). Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. The New England Journal of Medicine, 371(10), 906 - 917. https://doi.org/10.1056/NEJMoa1402551

@article{d4b489c5ca3a4e45868bcc7914ae5bd4,

title = "Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma",

abstract = "Background: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. Methods: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. Results: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P",

author = "Lotfi Benboubker and Dimopoulos, \{Meletios Athanasios\} and Angela Dispenzieri and John Catalano and Belch, \{Andrew R\} and Cavo, \{Michele M\} and Pinto, \{Antonello I\} and Weisel, \{Katja Christina\} and Heinz Ludwig and Bahlis, \{Nizar Jacques\} and Anne Banos and Mourad Tiab and Michel Delforge and Cavenagh, \{Jamie D\} and Catarina Geraldes and Jejung Lee and Christine Chen and Albert Oriol and \{De La Rubia\}, Javier and Lugui Qiu and White, \{Darrell J\} and Daniel Binder and Anderson, \{Kenneth Carl\} and Fermand, \{Jean Paul\} and Philippe Moreau and Michel Attal and Knight, \{Robert D\} and Guang Chen and \{Van Oostendorp\}, Jason and Christian Jacques and Ervin-Haynes, \{Annette L\} and Herve Avet-Loiseau and Cyrille Hulin and Thierry Facon",

year = "2014",

doi = "10.1056/NEJMoa1402551",

language = "English",

volume = "371",

pages = "906 -- 917",

journal = "The New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "10",

}

Benboubker, L, Dimopoulos, MA, Dispenzieri, A, Catalano, J, Belch, AR, Cavo, MM, Pinto, AI, Weisel, KC, Ludwig, H, Bahlis, NJ, Banos, A, Tiab, M, Delforge, M, Cavenagh, JD, Geraldes, C, Lee, J, Chen, C, Oriol, A, De La Rubia, J, Qiu, L, White, DJ, Binder, D, Anderson, KC, Fermand, JP, Moreau, P, Attal, M, Knight, RD, Chen, G, Van Oostendorp, J, Jacques, C, Ervin-Haynes, AL, Avet-Loiseau, H, Hulin, C & Facon, T 2014, 'Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma', The New England Journal of Medicine, vol. 371, no. 10, pp. 906 - 917. https://doi.org/10.1056/NEJMoa1402551

TY - JOUR

T1 - Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

AU - Benboubker, Lotfi

AU - Dimopoulos, Meletios Athanasios

AU - Dispenzieri, Angela

AU - Catalano, John

AU - Belch, Andrew R

AU - Cavo, Michele M

AU - Pinto, Antonello I

AU - Weisel, Katja Christina

AU - Ludwig, Heinz

AU - Bahlis, Nizar Jacques

AU - Banos, Anne

AU - Tiab, Mourad

AU - Delforge, Michel

AU - Cavenagh, Jamie D

AU - Geraldes, Catarina

AU - Lee, Jejung

AU - Chen, Christine

AU - Oriol, Albert

AU - De La Rubia, Javier

AU - Qiu, Lugui

AU - White, Darrell J

AU - Binder, Daniel

AU - Anderson, Kenneth Carl

AU - Fermand, Jean Paul

AU - Moreau, Philippe

AU - Attal, Michel

AU - Knight, Robert D

AU - Chen, Guang

AU - Van Oostendorp, Jason

AU - Jacques, Christian

AU - Ervin-Haynes, Annette L

AU - Avet-Loiseau, Herve

AU - Hulin, Cyrille

AU - Facon, Thierry

PY - 2014

Y1 - 2014

N2 - Background: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. Methods: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. Results: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P

AB - Background: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. Methods: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. Results: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P

UR - http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402551

U2 - 10.1056/NEJMoa1402551

DO - 10.1056/NEJMoa1402551

M3 - Article

SN - 0028-4793

VL - 371

SP - 906

EP - 917

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

IS - 10

ER -

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

Abstract

Access to Document

Other files and links

Cite this